GLP-1 medications have dominated the weight-loss landscape this year — but some older Americans are reportedly kicking the trend to the curb. A study published

While GLP-1 drugs promise an easy fix, our bodies still need what they have always needed: healthy food and regular exercise Prof Devi Sridhar is

Novo Nordisk and Eli Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China, according to the Danish ‌drugmaker and Chinese

If you’re starting a GLP-1 medication or have recently begun treatment, you’re probably wondering what to expect. Maybe you’ve heard stories about intense nausea or

Oprah Winfrey is opening up about her weight-loss journey. During a recent interview with People magazine, the 71-year-old television personality discussed her new book, “Enough,”

A review of 2025’s noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.

Key Points Eli Lilly is working on the acquisition of a France-based drugmaker. This could allow it to expand its footprint in the immunology market.

Everything seems to be going well for Eli Lilly (NYSE: LLY). The company’s shares have soared in recent years thanks to strong clinical progress within

As 2025 winds to a close, it is time once again to look back at some of the aging and longevity research published in the

Metabolic dysfunction-associated steatohepatitis (MASH) is a multifactorial metabolic liver disease that occurs in the context of obesity, insulin resistance and cardiometabolic comorbidities. Monotherapy targeting single

(MedPage Today) — An imaging study suggested prescription attention deficit hyperactivity disorder (ADHD) drugs may work differently than previously thought by affecting arousal and reward,

(MedPage Today) — The Trump administration announced a new demonstration program aimed at easing access to GLP-1 receptor agonists for enrollees in Medicare Part D

[link] [13 comments]

With markets up significantly, 2025 has likely been a great year for most SIPP and Stocks and Shares ISA investors. But what about next year?

Here are this week’s new releases for the category ‘Audiobooks’. ★ Our Staff Pick ★ Weightless: A Doctor’s Guide to GLP-1 Medications, Sustainable Weight Loss,

Here are this week’s new releases for the category ‘General’. ★ Our Staff Pick ★ What’s Your Dream?: Find Your Passion. Love Your Work. Build

Here are this week’s new releases for the category ‘Kindle’. ★ Our Staff Pick ★ The Rest of Our Lives: A Novel By Ben Markovits

Here are this week’s new releases for the category ‘Medicine’. ★ Our Staff Pick ★ Cases in Simulated Disaster Medicine By Andrew Milsten (Editor), John

Logic dictates that we load up our one stomach with one meal, and we’re done. For a few hours, at least. But as many of

As a physician-psychiatrist, I have watched the rise of GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) with genuine admiration. They are transforming metabolic health, reducing cardiovascular

Oprah Winfrey is opening up about her health. The 71-year-old mogul got candid in a new interview about using a GLP-1 weight loss medication, and

Mark Cuban, co-founder of Cost Plus Drugs Co., and Optum CEO Patrick Conway, MD, sparred over drug prices, pharmacy benefit managers and a range of

Oprah Winfrey says the disappearance of so-called food noise is one of the most amazing effects of her GLP-1 drug. Plus now she can take

I think this was a really bad year for American politics, a mediocre year for the American economy, and an exceptional year for America. In

The FDA has approved the first GLP-1 pill for weight loss and it’s expected in pharmacies in the coming weeks. Dr. Holly Lofton, director of

Trump and his throwback henchmen have set scientific research back for decades. This piece from the Atlantic (gift link) spells it out and it’s just

Talk show queen Oprah Winfrey, who will be turning 72 in January and will be releasing a new book she co-wrote with obesity expert Dr. Ania M.

Oprah Winfrey revealed she used to be able to ‘drink everyone under the table’ before GLP-1’s took away her desire for alcohol.

Medifast, Inc. MED is strategically transitioning beyond its traditional identity as a weight-loss company toward becoming a broader leader in metabolic health. As part of

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has consistently positioned technology and clinical infrastructure at the core of its operating

CMS introduced several new care and payment models in 2025, many focused on drug pricing, chronic disease management and prevention:  1. CMS published plans Dec.

Amgen AMGN is one of the few companies with a late-stage obesity candidate in its pipeline. The company is developing MariTide, an investigational GLP-1/GIP receptor

When glucagon-like peptide-1 (GLP-1) receptor agonists entered the market for obesity and overweight indications in recent years, the uptake and enthusiasm drove investor excitement for